Removing excess sFlt-1 from mothers' blood to help preeclampsia
New Therapeutic Strategy Against Preeclampsia : Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1 and Release of PlGF
This project will collect blood from pregnant people with and without preeclampsia to see which patients might benefit from removing excess sFlt-1 from the blood.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT06464159 on ClinicalTrials.gov |
What this trial studies
This is a prospective, non-interventional biobank collecting maternal plasma and serum from 50 pregnancies complicated by preeclampsia and 50 normal pregnancies at Port-Royal Maternity (Cochin APHP). Samples will be taken across defined gestational-age windows and analyzed for circulating angiogenic and anti-angiogenic factors (free and total forms), with most assays performed at the hormonology laboratory in Cochin hospital. The molecular profiles will be used to characterize angiogenic balance heterogeneity in preeclampsia and to optimize and validate extracorporeal sFlt-1 purification techniques. The goal is to identify which angiogenic profiles best correspond to a potential indication for apheresis.
Who should consider this trial
Good fit: Ideal candidates are pregnant people aged 18–50 with a singleton pregnancy between 20 and 41 weeks who have confirmed preeclampsia or are uncomplicated controls and can attend Port-Royal Maternity for blood collection.
Not a fit: People with multiple pregnancies, active HIV/HBV/HCV infection, under 18, without social security coverage, or whose preeclampsia is not driven by sFlt-1 excess are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could identify patients likely to benefit from extracorporeal sFlt-1 removal and help delay delivery or reduce maternal symptoms, improving outcomes for mother and baby.
How similar studies have performed: Small pilot studies and case reports of extracorporeal sFlt-1 removal have shown promising physiological and clinical signals, but larger randomized trials are still lacking.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 18 to 50 years old * Singleton pregnancies between 20 and 41 weeks of gestation * Preeclampsia / normal pregnancy Exclusion Criteria: * Age \< 18 years old * Infectious disease: HIV, HBV or HCV * Multiple pregnancies * refusal to participate in the protocol * Lack of social security cover
Where this trial is running
Paris
- Maternité Port-Royal — Paris, France (Recruiting)
Study contacts
- Principal investigator: Vassilis TSASARIS, MD, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Vassilis TSASARIS, MD, PhD
- Email: vassilis.tsasaris@aphp.fr
- Phone: +33 158413871
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.